BioCina and NovaCina collaborating on Drug Substance and Product Solutions for Biologics

This collaboration will enable both companies to offer comprehensive biopharmaceutical manufacturing solutions.

BioCina, a biologics contract development and manufacturing organization (CDMO) and NovaCina, a global fill-and-finish CDMO, have joined forces to provide integrated drug substance and drug product solutions for biologics developers. This will enable BioCina to offer fill/finish services by transforming drug substances made at its Adelaide, South Australia, sites into drug products at NovaCina’s facilities in Perth, Australia. This collaboration is focused on offering comprehensive biopharmaceutical manufacturing solutions.

BioCina focuses on providing CDMO services including cell line development, process development, and current good manufacturing practice clinical and commercial manufacturing for microbial, plasmid DNA, and messenger RNA modalities. It intends to set up a new location next to its Adelaide facility, previously a Pfizer site, to concentrate on mammalian Parkinson’s disease and large-scale manufacturing. NovaCina specializes in clinical and commercial fill/finish services, collaborating with regulatory agencies for various offerings such as development, manufacturing, packaging, labeling, and stability studies.

BioCIna is thrilled to collaborate with NovaCina, combining their expertise in clinical and commercial process development and drug substance manufacturing with their drug product services.

Source: BioCina